- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Therapeutic Areas
- Oncology
- Cystic Fibrosis
- Publications
- Programs
- Pipeline
- mTORC1/2 inhibitor Sapanisertib
- SYK Inhibitor Mivavotinib
- Arginase Inhibitor
Cystic Fibrosis - Preclinical Programs
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Therapeutic Areas
Publications and Presentations
Check out our publications and poster presentations.
April 2022
Identification of novel VPS4A inhibitors for the treatment of VPS4B-deleted cancersAmerican Association for Cancer Research
November 2021
A Phase 1b Randomized, Double-blind, Placebo-controlled, Dose Escalation Trial of CB-280, an Arginase Inhibitor, in Patients With Cystic FibrosisNorth American Cystic Fibrosis Conference
September 2021
KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2- Mutated Non-squamous Metastatic NSCLCWorld Conference on Lung Cancer
June 2021
CANTATA: Primary Analysis of a Global, Randomized, Placebo-Controlled, Double-Blind Trial of Telaglenastat (CB-839) + Cabozantinib vs. Placebo + Cabozantinib in Patients With Advanced/Metastatic Renal Cell Carcinoma that Progressed on Immune Checkpoint Inhibitor or Anti-Angiogenic TherapiesAmerican Society of Clinical Oncology
January 2021
A Phase 1/2 Study of Safety and Efficacy of the Arginase Inhibitor INCB001158 Plus Chemotherapy in Patients With Advanced or Metastatic Biliary Tract CancersASCO Gastrointestinal Cancers Symposium
Our Pipeline
We are focused on novel treatments for
cancer and other life-threatening diseases.